BSD Medical Reports Publication of Editorial Advocating Hyperthermia Treatment Published in The Lancet Oncology Business Wire SALT LAKE CITY -- May 28, 2014 BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com) today announced that an editorial advocating hyperthermia treatment was published in The Lancet Oncology, the premier worldwide journal for original oncology research. The editorial on the evolving role of hyperthermia in cancer therapy was titled “Hyperthermia in cancer: is it coming of age?" [The Lancet Oncol, Vol:15, Issue 6, pages 565-566, May 2014; doi: 10.1016/S1470-2045(14)70207-4.] The editorial was written by Professors Adam Januszewski and Justin Stebbing, Department of Surgery & Cancer, Imperial College London. The researchers reviewed the history of hyperthermia and discussed the biological mechanism of action that results in hyperthermia induced tumor cell death. The authors reviewed the published studies that have demonstrated impressive results from the use of hyperthermia for the treatment of cancer. The researchers concluded that, “The few, but impressive trials are evidence that this is not just an anecdotal technology, but one that warrants continued investment and investigation. The studies’ improvements in tumour response would generally be hailed a success had they been a pharmaceutical product. So far, hyperthermia requires trained personnel and specialized equipment; scepticism is often justified, but data are increasing and the design of ongoing studies is robust. It is time that this technology is given the attention it deserves.” About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s MicroThermX microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information. Contact: BSD Medical Corporation William (Bill) S. Barth, 801-972-5555 Fax: 801-972-5930 email@example.com
BSD Medical Reports Publication of Editorial Advocating Hyperthermia Treatment Published in The Lancet Oncology
Press spacebar to pause and continue. Press esc to stop.